Morgans tips Zip (ASX:Z1P) share price to jump 30%

Is it time to buy Zip shares?

It has been another largely disappointing month for the Zip Co Ltd (ASX: Z1P) share price.

Since the start of October, the buy now pay later (BNPL) provider's shares have fallen 7.5% to $6.53.

This means the Zip share price is now down 55% from its February high of $14.53.

A hipster dude leaps in the air with glee, seeing positive news on his tablet.

Image source: Getty Images

Can the Zip share price rebound?

Thankfully for shareholders, one leading broker believes the Zip share price can rebound strongly from here.

According to a recent note out of Morgans, its analysts have retained their add rating but trimmed their price target on the company's shares slightly to $8.56.

Based on the current Zip share price, this implies potential upside of 31% for its shares over the next 12 months.

What did the broker say?

Morgans felt that Zip delivered a reasonably solid first quarter update last week. Though, it does acknowledge that the company's growth will need to accelerate in order to reach consensus estimates.

The broker said: "We saw 1Q22 group sequential revenue growth of 8% as a reasonable outcome (in Z1P's seasonally weakest quarter) and highlighting continued momentum. However, with the FY22 consensus revenue forecast ($689m) implying +71% growth on pcp, Zip's sales growth trajectory needs to improve meaningfully over Q2-Q4 to hit this level."

"Our other key quarterly takeaways were; 1) while Z1P's ANZ net bad debt ratio of 2.43% was largely in-line with pcp, it has risen from 1.87% at 4Q21; 2) revenue margins in the US were called out as still being around 7%; and 3) transaction value per average customer continues to decline in Australia (A$90), being roughly half of the pcp level, reflecting the impacts of Tap and Zip functionality," it added.

Outside this, the broker reiterated that sees significant potential if Zip delivers on its bold plans and notes that the Zip share price trades at a huge discount to rival Afterpay Ltd (ASX: APT).

Morgans concluded: "We continue to see longer term upside if Z1P can execute on its ambitions of becoming a global payments player. Noting the stock continues to trade at a significant discount to peer APT (~6x sales versus ~25x), we maintain our ADD recommendation."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO and ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Couple using their digital tablet together.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

Why the Paladin Energy share price "doesn't make sense"

This uranium stock could be set for a major re-rating.

Read more »

Two miners standing together.
Broker Notes

3 ASX 200 mining shares to buy with 41% to 79% upside ahead: broker

The green energy transition and other factors are providing strong growth drivers for mining.

Read more »

Happy miner with his arms folded.
Broker Notes

Buy, hold, sell: Paladin Energy, Fortescue, Rio Tinto shares

Let's take a look at some new ratings from Morgans.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

9 ASX 200 shares experts are backing for growth amid market weakness

Brokers retained a positive view on BHP, CSL, Telstra, Xero, and other shares this week. 

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

This ASX biotech could rise 40% or 750%, depending on who you ask

A poor quarter has reduced expectations, but there's still plenty of upside.

Read more »

Man using his device in an airport.
Broker Notes

This high-quality ASX 200 share could rise 60%

A leading broker expects a good yield and major upside from this stock.

Read more »

A baby's eyes open wide in surprise as it sucks on a milk bottle.
Broker Notes

Trading near 12-month lows, this ASX retailer could be set for a 54% gain

This baby goods retailer still has ample room to grow.

Read more »